These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis. Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250 [TBL] [Abstract][Full Text] [Related]
24. A network-biology approach for identification of key genes and pathways involved in malignant peritoneal mesothelioma. Mahfuz AMUB; Zubair-Bin-Mahfuj AM; Podder DJ Genomics Inform; 2021 Jun; 19(2):e16. PubMed ID: 34261301 [TBL] [Abstract][Full Text] [Related]
25. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells. Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178 [TBL] [Abstract][Full Text] [Related]
26. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma. Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963 [TBL] [Abstract][Full Text] [Related]
27. Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma. Arzt L; Halbwedl I; Gogg-Kamerer M; Popper HH Pathol Oncol Res; 2017 Jul; 23(3):595-605. PubMed ID: 27987139 [TBL] [Abstract][Full Text] [Related]
28. Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients. Lamberti M; Capasso R; Lombardi A; Di Domenico M; Fiorelli A; Feola A; Perna AF; Santini M; Caraglia M; Ingrosso D PLoS One; 2015; 10(8):e0135331. PubMed ID: 26262875 [TBL] [Abstract][Full Text] [Related]
30. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival. Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477 [TBL] [Abstract][Full Text] [Related]
31. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification. Tian K; Bakker E; Hussain M; Guazzelli A; Alhebshi H; Meysami P; Demonacos C; Schwartz JM; Mutti L; Krstic-Demonacos M J Transl Med; 2018 Oct; 16(1):282. PubMed ID: 30316293 [TBL] [Abstract][Full Text] [Related]
32. High Expression of Deng H; Huang Y; Wang L; Chen M Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373 [TBL] [Abstract][Full Text] [Related]
33. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis]. Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141 [No Abstract] [Full Text] [Related]
34. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535 [TBL] [Abstract][Full Text] [Related]
35. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma. Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538 [TBL] [Abstract][Full Text] [Related]
36. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component. Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615 [TBL] [Abstract][Full Text] [Related]
37. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624 [TBL] [Abstract][Full Text] [Related]
38. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy. Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978 [TBL] [Abstract][Full Text] [Related]
39. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer. Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036 [TBL] [Abstract][Full Text] [Related]
40. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. Melaiu O; Stebbing J; Lombardo Y; Bracci E; Uehara N; Bonotti A; Cristaudo A; Foddis R; Mutti L; Barale R; Gemignani F; Giamas G; Landi S PLoS One; 2014; 9(1):e85935. PubMed ID: 24465798 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]